Showing results (61-70 of 165) with videos related to
Sort By:
Pageof 17
Blood Neoplasia|September 15, 2025
Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplantBrian Cuzzo, Maegan Ford, Saagar Jain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortiumSonali M Smith, Koen van Besien, Theodore Karrison, et al.Leukemia & Lymphoma|August 11, 2025
Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphomaEmily R Gordon, Seda Tolu, Brigit A Lapolla, et al.British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantationMaricer P Escalón, Richard E Champlin, Rima M Saliba, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.Pageof 17